Martina Okwueze, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 969 Tennessee Ave S, Parsons, TN 38363 Phone: 731-847-1236 |
News Archive
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced.
A recent study by Canadian and US researchers demonstrates how frameshift signals of coronaviruses represent a viable target for developing novel therapeutics with broad-spectrum activity – not only against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other constituents of the coronavirus family. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.
A new international study published today in The Lancet provides the clearest picture yet of the impact and most common causes of diarrheal diseases, the second leading killer of young children globally, after pneumonia.
New evidence presented at the European Congress of Endocrinology has shown that vitamin D deficiency is closely associated with the chronic fatigue that often follows post traumatic brain injury.
› Verified 5 days ago